AI Analysis
AI-generated analysis. Always verify with the original filing.
Actinium reported $90.0K in revenue and a net loss of $33.9M for FY2025 — reflecting continued pre-commercial operations and disciplined cost management amid persistent R&D intensity and negative free cash flow of $24.7M.
Key Takeaways
1Revenue rose 11.1% to $90.0K, solely from a single NIH grant supporting the Iomab-ACT clinical collaboration — no commercial product revenue was generated.
2Operating income improved 13.9% to -$36.2M, driven by lower cash compensation and reduced CRO services, consistent with workforce optimization and preclinical R&D prioritization.
3Capital expenditures increased to $104K as construction began on a modular manufacturing space — advancing internal Ac-225 supply capability while maintaining reliance on DOE-sourced material.
4Free cash flow was -$24.7M, calculated as operating cash use of $24.6M less $104K in capital expenditures — underscoring the company’s ongoing capital-intensive, pre-revenue stage.